- Home
- TRVI vs TERN Comparison
TRVI vs TERN Comparison
Compare TRVI & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- TERN
- Stock Information
- Founded
- TRVI 2011
- TERN 2017
- Country
- TRVI United States
- TERN United States
- Employees
- TRVI N/A
- TERN N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- TERN Health Care
- Exchange
- TRVI Nasdaq
- TERN Nasdaq
- Market Cap
- TRVI 341.4M
- TERN 382.2M
- IPO Year
- TRVI 2019
- TERN 2021
- Fundamental
- Price
- TRVI $3.76
- TERN $4.43
- Analyst Decision
- TRVI Strong Buy
- TERN Buy
- Analyst Count
- TRVI 8
- TERN 5
- Target Price
- TRVI $9.31
- TERN $18.30
- AVG Volume (30 Days)
- TRVI 659.4K
- TERN 1.9M
- Earning Date
- TRVI 11-06-2024
- TERN 03-13-2025
- Dividend Yield
- TRVI N/A
- TERN N/A
- EPS Growth
- TRVI N/A
- TERN N/A
- EPS
- TRVI N/A
- TERN N/A
- Revenue
- TRVI N/A
- TERN N/A
- Revenue This Year
- TRVI N/A
- TERN N/A
- Revenue Next Year
- TRVI N/A
- TERN N/A
- P/E Ratio
- TRVI N/A
- TERN N/A
- Revenue Growth
- TRVI N/A
- TERN N/A
- 52 Week Low
- TRVI $1.27
- TERN $4.32
- 52 Week High
- TRVI $4.68
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- TRVI 48.03
- TERN 26.46
- Support Level
- TRVI $3.63
- TERN $4.56
- Resistance Level
- TRVI $4.06
- TERN $5.95
- Average True Range (ATR)
- TRVI 0.30
- TERN 0.29
- MACD
- TRVI -0.09
- TERN -0.10
- Stochastic Oscillator
- TRVI 12.21
- TERN 3.17
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.